News

Atypical ANCAs Do Not Contribute to Vessel Inflammation in Patients with Eye Disease, Study Suggests

The presence of atypical ANCA antibodies in people with underlying eye inflammatory disease is not linked to severe vessel inflammation or worse outcomes, a small study reports. The study, “Atypical Perinuclear Anti-Neutrophil Cytoplasmic Antibodies in Ocular Inflammatory Diseases,” was published in the journal Ocular Immunology and Inflammation. ANCA-associated…

ANCA Vasculitis Maintenance Therapy Imuran Causes Allergic Reaction in Kidneys, Case Report Shows

A patient taking Imuran (azathioprine) to treat his ANCA-associated vasculitis experienced an acute allergic reaction to the therapy which manifested as a kidney inflammation. Researchers should be aware of this complication to promptly distinguish disease relapse from acute reactions to the medicine. The case report, “Azathioprine-induced interstitial nephritis…

Cigarettes Caused Smoker with Interstitial Lung Disease to Produce ANCA Antibodies, Report Says

In patients with interstitial lung disease, cigarette smoking may sometimes cause the production of ANCA associated antibodies — a hallmark of ANCA-associated vasculitis — without any signs of vessel inflammation, the case of a 57-year-old man suggests. The case report, “Combined pulmonary fibrosis and emphysema with myeloperoxidase-antineutrophil cytoplasmic antibody…

Head and Neck Symptoms Can Indicate GPA, So Clinicians Must Be Watchful

Alterations in the nasal cavity mucosa and throat often are primary symptoms of granulomatosis with polyangiitis (GPA) and it is critical that otolaryngologists are aware of the disease’s head and neck manifestations, researchers say. In a case report, Mayo Clinic researchers highlight some common endoscopic and radiologic findings seen…

Antiviral Therapy May Reduce Risk of Infection in AAV Patients, Clinical Study Suggests

Antiviral therapy prevents silent reactivation of cytomegalovirus (CMV) in ANCA-associated vasculitis (AAV) patients and improves patients’ immune responses, a proof-of-concept clinical study shows. These results suggest that antiviral therapy may reduce the risk of infection in these patients. The study, “Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion…